TPI 1020

Drug Profile

TPI 1020

Alternative Names: NCX 1020; NO-budesonide; TPI-1020

Latest Information Update: 14 Jan 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NicOx
  • Developer NicOx; Topigen Pharmaceuticals
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Immunosuppressants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Jan 2010 Discontinued - Phase-II for Asthma in Canada (Inhalation)
  • 14 Jan 2010 Discontinued - Phase-II for Asthma in Europe (Inhalation)
  • 16 Sep 2009 Preclinical pharmacodynamics data in Bronchial disorders presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top